Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Medigus ($MDGS) announced that it has been granted new patents with regard to its micro ScoutCam miniature camera technology. These patents have been granted by the Japanese Patent Office  and the European Patent Office. The ScoutCam portfolio consists of a range of video cameras with small diameter heads which Complementary Metal Oxide Semiconductor (CMOS) or Charge-coupled Device (CCD) based sensors.
The company stock gained close to 5 percent in the previous trading session, trimming its 12 months loss to 87 percent. The Japanese patent is valued until September 16, 2030 and will be the first patent Medigus receives for integrated endoscope irrigation.

Cellular Biomedicine Group Inc. ($CBMG) stock surged over 60 percent as the company announced that addition of a second site to its Phase 1 clinical trial assessing of CAR-T candidate C-CAR011. The drug is being developed for treating patients with relapsed/refractory B cell non-Hodgkin lymphoma. The study, designated CARD-1, plans to enroll 15 subjects comprised of DLBCL, Primary Mediastinal Large B-Cell Lymphoma (PMBCL) and Follicular Lymphoma (FL).
The company stock has lost 34 percent of its value this year so far while its 12 months loss stands at 44 percent. Cellular is  engaged in the development of treatments for cancerous and degenerative diseases utilizing cell-based technologies.

 

MabVax Therapeutics ($MBVX) announced a public offering of $4.1 million. The company plans to the use the proceeds for funding  three Phase 1 clinical trials for its antibody therapeutic, diagnostic, and radioimmunotherapy candidates, as well as follow-on programs.

GW Pharmaceuticals ($GWPH) announced that it has appointed Volker Knappertz, M.D. as its new Chief Medical Officer and Professor Ben Whalley as the new Head of Discovery Research. Dr. Knappertz joins the firm from Teva where he was VP of Clinical Development for multiple sclerosis.

Teva Pharmaceuticals Industries ($TEVA) announced the launch of the generic version of diabetes med Glumetz in the United States. The market is estimated to be worth nearly $1.03 billion, as per IMS Health.

Biohaven Pharmaceuticals Holdings ($BHVN) announced that its  trigriluzole has received Fast Track review designation from the FDA for the treatment of spinocerebellar ataxia. The product candidate is currently in Phase 2/3 development and its top-line data is expected to be released next year.

 

Akebia Therapeutics ($AKBA) and Vifor Pharma Group announced inking an exclusive licensing deal with Fresenius Medical Care to supply vadadustat to its dialysis clinics upon U.S. regulatory approval. Under the terms of the deal, Vifor will exclusively distribute vadadustat to Fresenius Medica Care North America. The profits will be shared with Akebia.

Cardiome Pharma ($CRME) announced that it has updated its loan agreement with CRG-managed funds. Under the terms of the original agreement, CRG provided $20M to the company for working capital and to retire existing debt. The new update provides for up to $50 million in borrowing capacity.  

 

Retractable Technologies Inc. ($RVP) announced that it incurred a loss of $0.04 per share for the first quarter of the year. Its total net loss for the quarter stood at $1.2 million. The company’s quarterly revenue stood at $6.9 million.
Electromed Inc. ($ELMD) announced its net revenue for the third quarter at $6.7 million, up 10.5 percent from $6.0 million it had reported for the corresponding previous quarter. Its operating income grew 40.9% to $1.0 million from $736,000 in Q3 FY 2016, while its net income expanded 38.9% to $648,000, or $0.08 per diluted share, from $467,000, or $0.06 per diluted share, in Q3 FY 2016.

Brokerage
Action
Company
Rating
Price Target
Impact on Share Price
Goldman Sachs Group
Initiates
Abbott Laboratories (ABT)
Neutral

Low
Stifel Nicolaus
Raises Target
Aetna (AET)
Buy
$150.00 -> $158.00
Low
Goldman Sachs Group
Initiates
Baxter International (BAX)
Conviction-Buy

Low
Goldman Sachs Group
Initiates
Boston Scientific (BSX)
Neutral

Low
Wedbush
Reiterates
Cidara Therapeutics (CDTX)
Outperform
$13.00
Low
Goldman Sachs Group
Initiates
Edwards Lifesciences Corp (EW)
Conviction-Buy

Low
Wedbush
Reiterates
Fate Therapeutics (FATE)
Outperform
$7.00
Low
Rodman & Renshaw
Raises Target
HTG Molecular Diagnostics (HTGM)
Buy
$4.50 -> $6.00
Low
Goldman Sachs Group
Initiates
Intuitive Surgical (ISRG)
Buy

Low
Goldman Sachs Group
Initiates
Medtronic plc. (MDT)
Neutral

Low

Gainers (% price change) Last Trade Change Mkt Cap
Alnylam Pharmaceuticals ALNY 66.00 +9.23 (16.26%) 5.83B
ImmunoGen, Inc. IMGN 4.56 +0.46 (11.22%) 420.77M
Nova Measuring NVMI 25.48 +1.68 (7.06%) 680.93M
Horizon Pharma PLC HZNP 10.75 +0.56 (5.50%) 1.71B
RadNet Inc. RDNT 6.85 +0.35 (5.38%) 328.49M
Losers (% price change)
Synergy Pharmaceuticals SGYP 3.97 -0.36 (-8.31%) 996.63M
Impax Laboratories Inc IPXL 16.80 -0.85 (-4.82%) 1.28B
Addus Homecare Corp. ADUS 37.90 -1.65 (-4.17%) 432.66M
EXACT Sciences Corp. EXAS 32.43 -1.34 (-3.97%) 3.54B
Kindred Healthcare, Inc. KND 10.40 -0.40 (-3.70%) 916.04M
Most Actives (dollar volume)
Johnson & Johnson JNJ 126.99 +3.37 (2.73%) 343.31B
Pfizer Inc. PFE 33.12 +0.11 (0.33%) 197.05B
EXACT Sciences Corp. EXAS 32.43 -1.34 (-3.97%) 3.54B
Valeant Pharmaceuticals VRX 14.17 +0.58 (4.27%) 4.75B
Humana Inc HUM 231.11 -0.88 (-0.38%) 33.53B